Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA
· The US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) Application for the combination of TG01 and QS-21 STIMULON™ · The IND is a major milestone for the TG mutant RAS program, and represents the first time that a TG vaccine is authorized for clinical trials in the USA Oslo, Norway, 23 June 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the US FDA has approved an IND application for TG01 combined with QS-21 STIMULON, which allows the